AMGN Finds New Use For Old Drug, NLNK Disappointed, ECYT Cuts Workforce

Today's Daily Dose brings you news about Amgen's multiple myeloma trial results with XGEVA; Merck's findings from Cohort 1 of phase 2 registrational trial of KEYTRUDA in gastric cancer patients and NewLink's disappointment in phase II trial of Indoximod in breast cancer.

from RTT - Biotech http://ift.tt/2suyyxU
via IFTTT